Its unique mechanism, which utilizes a bystander effect to target tumor cells irrespective of HER-2 expression levels, is particularly advantageous in GC, a disease frequently characterized by heterogeneous HER2 expression [92]. This evidence concerns the gene ERBB2 and neoplasm.